Platinum Priority – Prostate CancerEditorial by XXX on pp. x–y of this issuePan-cancer Analysis of CDK12 Alterations Identifies a Subset of Prostate Cancers with Distinct Genomic and Clinical Characteristics
Introduction
Genomic alterations in CDK12 have been observed in various cancer types [1], [2], [3], [4] but their oncogenic function and clinical relevance are poorly understood. CDK12 encodes a cyclin-dependent serine/threonine kinase involved in the regulation of the cell cycle and of DNA repair by homologous recombination (HR). Specifically, it has been shown that CDK12 loss of function suppresses the expression of several HR genes, at least in part, via intronic polyadenylation [5], [6], [7], [8]. Growing evidence suggests that biallelic CDK12 loss determines a distinct phenotype of ovarian and prostate cancer characterized by high genomic instability and tandem duplications [9], [10], [11].
It has been reported that CDK12 alterations occur in 4–11% of prostate cancer cases and are more frequent in the metastatic castration-resistant setting (mCRPC) [3], [9], [12]. Despite preclinical work suggesting that CDK12 loss or inhibition could impair genes in the HR repair pathway, recent evidence has shown that PARP inhibitors have limited efficacy in mCRPC patients harboring a CDK12 alteration [13], [14]. However, Wu and colleagues [9] recently demonstrated that CDK12 loss determines a novel molecular subtype of prostate cancer associated with a higher proportion of fusion neoantigens and potentially high immune infiltration and response to anti–PD1/PD-L1 agents.
In this study we sought to survey the landscape of CDK12 mutations across different cancer types. We identified prostate cancer as the cancer type with the highest prevalence of CDK12 oncogenic alterations and the largest proportion of truncating variants, with biallelic inactivation occurring frequently, and characterized the genomic architecture of CDK12-altered prostate carcinomas. We describe clinicopathologic characteristics and clinical outcomes for patients with prostate cancers harboring CDK12 alterations. Our work adds to recent publications [15], [16] by integrating pan-cancer genomic analysis from a clinical sequencing assay, identifying distinct genomic alterations associated with CDK12-altered prostate cancer, and describing clinical features of the largest set of prostate cancer patients with CDK12 alterations identified using a single assay.
Section snippets
Study design and patients
All patients in the study underwent tumor sequencing performed using the Memorial Sloan Kettering Integrated Molecular Profiling of Actionable Cancer Targets (MSK-IMPACT) clinical sequencing assay, a hybridization capture-based, next-generation sequencing platform, with 341, 410, or 468 genes (all panels included CDK12) [17], [18]. After excluding 1965 cases with high microsatellite instability (MSI) cases, defined as an MSI sensor [19] score >10, and/or high tumor mutation burden (TMB) cases,
Landscape of CDK12 alterations across cancer types
We assessed the prevalence of CDK12 alterations among 26743 patients across 25 solid cancer types profiled using the MSK-IMPACT clinical sequencing test. A total of 404 patients (1.5%) had tumors with at least one CDK12 alteration. Prostate (n = 100/1875, 5.3%) and ovarian (n = 43/1034, 4.2%) cancers were the types with the highest frequencies of CDK12 oncogenic alterations (Fig. 1A), including somatic point mutations, rearrangements, and deep deletions. Using MutSigCV [22], we found that CDK12 was
Discussion
We analyzed the prevalence and types of somatic CDK12 alterations across >26000 tumors spanning 25 cancer types and found that prostate and ovarian cancers were the malignancies with the highest prevalence of CDK12 alterations, similar to a recent report [15]. The overall prevalence of CDK12 alterations in prostate cancer was 5.3%, which falls within the previously reported range [3], [15]. The majority of CDK12 alterations in these cancers were oncogenic and clonal and resulted in biallelic
Conclusions
In summary, our results suggest that CDK12 loss of function defines a distinct subset of disease associated with unique genomic alterations and somewhat worse clinical outcomes, and highlights the need for novel therapies targeting CDK12-altered prostate cancer.
Author contributions: Wassim Abida had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Study concept and design: Nguyen, Mota, Nandakumar, Gopalan,
CRediT authorship contribution statement
Bastien Nguyen: Data curation, Formal analysis, Investigation, Methodology, Visualization, Writing - original draft, Writing - review & editing. Jose Mauricio Mota: Data curation, Formal analysis, Investigation, Methodology, Writing - original draft, Writing - review & editing. Subhiksha Nandakumar: Data curation, Formal analysis, Investigation, Methodology, Visualization, Writing - review & editing. Konrad H. Stopsack: Methodology, Validation, Writing - review & editing. Emily Weg: Writing -
References (26)
- et al.
Integrative clinical genomics of advanced prostate cancer
Cell
(2015) - et al.
Genomic hallmarks and structural variation in metastatic prostate cancer
Cell
(2018) - et al.
Clinical outcomes in cyclin-dependent kinase 12 mutant advanced prostate cancer
Eur Urol
(2020) - et al.
MSK-IMPACT: a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology
J Mol Diagn
(2015) - et al.
Oncogenic signaling pathways in The Cancer Genome Atlas
Cell
(2018) - et al.
Structural alterations driving castration-resistant prostate cancer revealed by linked-read genome sequencing
Cell
(2018) - et al.
Integrated genomic analyses of ovarian carcinoma
Nature
(2011) - et al.
The \tancer
Cell
(2015) - et al.
The long tail of oncogenic drivers in prostate cancer
Nat Genet
(2018) - et al.
Ovarian carcinoma CDK12 mutations misregulate expression of DNA repair genes via deficient formation and function of the Cdk12/CycK complex
Nucleic Acids Res
(2015)
The cyclin K/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genes
Genes Dev
CDK12 activates HRR by suppressing intronic polyadenylation, 2018
Nature
CDK12 loss in cancer cells affects DNA damage response genes through premature cleavage and polyadenylation
Nat Commun
Cited by (71)
Metastatic prostate cancer is associated with distinct higher frequency of genetic mutations at diagnosis
2023, Urologic Oncology: Seminars and Original InvestigationsGenetic aberrations of homologous recombination repair pathways in prostate cancer: The prognostic and therapeutic implications
2023, Advances in Medical SciencesCell-free DNA in the management of prostate cancer: Current status and future prospective
2023, Asian Journal of UrologyChromosome 8q arm overexpression is associated with worse prostate cancer prognosis
2023, Urologic Oncology: Seminars and Original InvestigationsCurrent progress and novel strategies that target CDK12 for drug discovery
2022, European Journal of Medicinal ChemistryCitation Excerpt :Alterations in the CDK12 genome have been observed in various cancers, but little is known about its oncogenic function and clinical relevance. A large number of clinical studies have found that among the tumors caused by CDK12 mutations, prostate cancer, colon cancer, and ovarian cancer are the most common [62–65]. Analysis of metastatic castration-resistant prostate cancer (mCRPC) samples identified a new subtype of prostate cancer caused by biallelic deletion of CDK12 [66].